This October 19-24, the American Association for the Study of Liver Disease (AASLD) will hold its annual gathering, The Liver Meeting, in Washington, D.C. This year’s meeting is quite notable as Anna S. Lok, MD, FAASLD, will be concluding her term as the 68th President of the association. During her tenure, Anna continued to lead the fight against viral hepatitis and to raise awareness that NAFLD is emerging as our next national epidemic. Congratulations to Anna for her outstanding leadership!

2017 has been a year of accomplishment and vigorous growth for the Division of Gastroenterology and Hepatology at Michigan Medicine, under the leadership of Division Chief, Dr. Chung Owyang. We are proud to be ranked nationally by US News & World Report as the 9th Best Program in Gastroenterology & GI Surgery. Our faculty have grown to more than 80 full time clinical and research faculty and we have expanded on both our clinical and research fronts. Our Liver Program has expanded its clinical footprint in the state of Michigan with new Hepatology clinics now offered at the Michigan Medicine – Metro Health Campus in Grand Rapids and a newly opened Advanced Hepatology Clinic in Midland. These complement our existing satellite clinics in Canton, Brighton, and Northville as well as our main campus in Ann Arbor. The Wilson Disease clinic under the direction of Dr. Fred Askari continues to be a destination center for patients from across the nation. Dr. Neehar Parikh was recently appointed Director of our Liver Tumor Clinic, which continues to be one of the largest such programs in the nation. On the research front, Drs. Grace Su and Tom Wang have developed significant innovations in the field of imaging technologies in the early detection of liver cancer while Dr. Elizabeth Speliotes continues her research on NAFLD and Personalized Medicine. In the past year, we have reached out to our partners within the community and hosted several one day “Hepatitis C Boot Camps” to share best practices. Our adult liver transplant service is well known for excellence. I am delighted to announce our one-year survival rate in this area is at 95%, making our program one of the top five in the country!

This year the Michigan Medicine Hepatology Program continues its strong tradition of participation and leadership at The Liver Meeting with highlights including 22 oral- or moderated- presentations and 26 poster presentations throughout the meeting. We are proud that 16 of our Hepatology faculty will represent Michigan Medicine as leaders at The Liver Meeting on multiple fronts including public policy issues to eradicate viral hepatitis, addressing the national opioid epidemic, and raising awareness of the growing burden of alcoholic and NAFLD in the US and abroad. The Division will host a reception and I invite all our faculty, fellows, and alumni to join their colleagues in celebration of our many accomplishments.

Sincerely,

Robert J. Fontana, M.D., FAASLD
Professor of Medicine
Anna S. F. Lok, MD, FRCP, FAASLD

AASLD President 2017

Anna Suk-Fong Lok, MD, FAASLD

68th President of the American Association of the Study of Liver Diseases

Given her prestigious career, it was no surprise that Anna S. F. Lok, MD, FAASLD, the Alice Lohrman Andrews Research Professor of Hepatology and Assistant Dean for Clinical Research at Michigan Medicine, was selected to become the 68th President of the AASLD in 2017. Anna has distinguished herself as an outstanding Clinician, Researcher, Educator, and Leader over the past 30+ years.

In 1995, Michigan was fortunate to attract Anna to lead our Hepatology Program. Since that time, she has helped foster the growth of the program from 4 to 16 full-time faculty. She has mentored numerous residents and fellows including international fellows. In addition, she has helped guide the career development of many junior faculty to highly successful independent research careers. Anna has also been an advocate in public policies and has worked with the CDC and WHO towards global elimination of viral hepatitis. The worldwide impact she has made for clinical practice in the areas of viral Hepatology cannot be overstated. Anna has published more than 450 papers and has an h-index >100. She also authored 24 topics in the widely used UpToDate series, and was the lead author of 4 editions of the widely read AASLD HBV guidelines. She is also a co-editor of the classical textbook Sherlock’s Diseases of the Liver and Biliary System, a tribute to her mentor the late Dame Sheila Sherlock. Anna has received numerous awards including a Distinguished Service Award from the AASLD, the Beaumont Prize from AGA, and an Honorary DSc degree from her alma mater—the University of Hong Kong, among others.

We are very proud of Anna’s accomplishments and her election as the 68th President of the AASLD. In honor of Anna’s contribution to Hepatology and to the Michigan Hepatology Program, the University of Michigan has established the Lok Breakthrough Research Fund with the goal of providing pilot grants to fellows and faculty. To date, over $800,000 has been raised thanks to contributions from you and other friends and patients who believe in Anna and her team, we are very close to the target of $1 million. If you wish to make a contribution to this Fund, please contact Lori Hirshman at (734) 763-6080 or hirshmal@umich.edu. Online gifts can be made on our website http://victors.us/lokresearch.
The Hepatology Program at Michigan Medicine ([http://www.med.umich.edu/hepatology/](http://www.med.umich.edu/hepatology/)) is one of the largest and most well-established programs in the country. We specialize in the diagnosis and management of acute liver failure, hepatitis B and C, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, Wilson disease, cirrhosis of any cause, hepatocellular carcinoma (liver cancer), liver transplantation, and complications of portal hypertension.

Our mission is to provide state-of-the-art, innovative, and compassionate care to patients affected by liver diseases through general Hepatology, viral hepatitis, Wilson disease, liver tumor, and liver transplantation clinics. As part of this mission, we provide multidisciplinary care so patients can be evaluated by physicians from all appropriate disciplines during a single visit. In addition, we are actively engaged in clinical research including novel therapies, improved diagnostic modalities, and better biomarkers and predictors of outcome. All patients seen in any of our Hepatology Clinics who are potential candidates for new therapies and other research protocols are referred for participation in clinical trials.

Headed by Anna Lok, MD, FRCP, the Hepatology Program includes sixteen faculty members with expertise in a wide variety of liver diseases. Our faculty play key roles in multiple NIH-sponsored clinical research networks, including acute liver failure, biomarkers for early diagnosis of hepatocellular carcinoma, drug-induced liver injury, and hepatitis B.

We are also involved in many clinical trials supported by pharmaceutical companies. These trials evaluate new therapies for various liver diseases including hepatitis B and C, fatty liver, alcoholic cirrhosis, and hepatocellular carcinoma.
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Robert J. Fontana</td>
<td>Oral Presentation and Moderator: Hepatotoxicity SIG: Incidence and differential diagnosis of abnormal liver biochemistries in oncology patients</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Grace L. Su</td>
<td>Meet-the-Professor Luncheon 15: Assessing Medical Co-morbidities in Liver Transplant Candidates</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>Anna S.F. Lok</td>
<td>Presentation: Annual Members Forum and Business Meeting</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Elizabeth K. Speliotes</td>
<td>EMW 20: Are Genetics Responsible for NAFLD/NASH?</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Grace L. Su</td>
<td>EMW 29: Challenges of Liver Disease During Pregnancy</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Robert J. Fontana</td>
<td>Moderator: Parallel Session 1 - Location: Room 152: Drug and Herbal Induced Liver Injury</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Robert J. Fontana</td>
<td>#13 Oral Presentation: Parallel Session 1: Drug and Herbal Induced Liver Injury: Minocycline and Anti-epileptics are the leading causes of DILI in Children: A report from the US DILIN</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Robert J. Fontana</td>
<td>#16 Oral Presentation: Parallel Session 1: Drug and Herbal Induced Liver Injury: Testing for Hepatitis C Virus RNA is Recommended for Patients with Suspected DILI</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Robert J. Fontana</td>
<td>#43: Parallel Session #6: Predictors and Risk Factors of Drug Hepatotoxicity: Candidate Liver Safety Biomarkers Provide Diagnostic and Mechanistic Insights in Patients with DILI</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Elliot Tapper</td>
<td>SIG Talk: Quality Improvement</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Jessica Mellinger</td>
<td>SIG Talk: Mixed Methods Approaches</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Monica Konerman Neehar Parikh</td>
<td>#212: Oral Presentation: Frequency, Evaluation and Subsequent Clinical Outcomes of Cirrhosis Patients with Abnormal Imaging Findings during Surveillance for Hepatocellular Carcinoma</td>
</tr>
</tbody>
</table>
# Oral Presentations and Session Moderators

## Sunday, October 22, 2017 (con’t)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 pm</td>
<td>Anna S.F. Lok</td>
<td>Presentation: President’s Address</td>
</tr>
<tr>
<td>4:45 pm</td>
<td>Anna S.F. Lok</td>
<td>Moderator: President’s Choice Lecture: Lipids, Lipases, Lipoproteins and Liver Disease</td>
</tr>
</tbody>
</table>

## Monday, October 23, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 am</td>
<td>Elliot B. Tapper</td>
<td>EMW 46: Preventing Hospital Re-admissions</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Anna S.F. Lok</td>
<td>Moderator: Presidential Plenary Session I</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Anna S.F. Lok</td>
<td>Remarks: Distinguished Awards Presentation</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Jessica Mellinger</td>
<td>#169: The Rising Healthcare Burden of Alcoholic Cirrhosis in the United States</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Anna S.F. Lok</td>
<td>Moderator: CDC Session on elimination of viral hepatitis</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Anna S.F. Lok</td>
<td>Remarks: AASLD Foundation Awards Recognition</td>
</tr>
<tr>
<td>4:15 pm</td>
<td>Elliot Tapper</td>
<td>#222: Oral Presentation: Sarcopenia and Opiate Use May Be Modifiable Risk Factors for Incident Overt Hepatic Encephalopathy: A Prospective Study</td>
</tr>
</tbody>
</table>
Poster Sessions

Friday, October 20, 2017  12:00 PM—1:30 PM

#473
Predicting the risk of hepatic encephalopathy in patients with cirrhosis: A risk score including longitudinal data and potential benefit of statins
Elliot B. Tapper, David Ratz, Jessica L. Mellinger, Anna S. Lok, Grace L. Su

#725
The CT Scan as Crystal Ball: Analytic Morphomics Predicts Mortality in Patients with Chronic Liver Disease
Elliot B. Tapper, Peng Zhang, Venkat Krishnamurthy, Sameer Saini, Stewart C. Wang, Grace L. Su

Saturday, October 21, 2017  2:00 PM—7:00 PM

#802
An Ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients
Michael L. Schilsky, Frederick K. Askari, Peter Ferenci, Aftab Ala, Anna Czlonkowska, David J. Nicholl, Jeffrey Bronstein, Danny Bega, Karl Heinz Weiss

#910
The combination of entecavir and peginterferon alfa-2a in HBeAg-positive immune tolerant (IT) adults with chronic hepatitis B virus (HBV) infection: Results of the HBRN IT Trial
Jordan J. Feld, Norah Terrault, Steven H. Belle, Raymond T. Chung, Naoky C. Tsai, Mandana Khalili, Robert P. Perrillo, Stewart Cooper, Marc G. Ghany, Harry L. Janssen, Anna S. Lok

#993
HIV testing in patients starting HCV treatment and factors associated with adherence to AASLD-IDSA Guidelines

#1009
Impact of an Electronic Medical Record Alert on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers in Primary Care Clinics
Monica A. Konerman, Mary Thomson, Kristen Gray, Meghan Moore, Hetal Choxi, Elizabeth Seif, Anna S. Lok

#1072
Predictive features of clinical improvement or deterioration for patients with decompensated hepatitis C cirrhosis after direct acting antiviral therapy
Poster Sessions

Saturday, October 21, 2017 (con’t) 2:00 PM—7:00 PM

#1096
Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
Charles S. Landis, Mark S. Sulkowski, Nancy Reau, Glen A. Lutchman, Monika Vainorius, Tania M. Weizel, Stefan Zeuzem, Mandana Khalili, David R. Nelson, Anna S. Lok, Michael W. Fried, Norah Terrault

#1134
Baseline Characteristics and Patient-Reported Outcomes (PROs) from PROP UP: A Large US Multi-site Observational Study of Patients with Chronic Hepatitis C (HCV) Initiating Direct Acting Antiviral Therapy (DAA)

Sunday, October 22, 2017 12:30 PM—2:00 PM

#1319
“You Gotta Want It”: Misconceptions, Preferences, and Barriers to Alcohol Use Treatment in Alcoholic Liver Disease
Jessica L. Mellinger, Melissa DeJonckheere, Gerald S. Winder, Robert J. Fontana, Michael Volk, Anna S. Lok, Frederic Blow

#1320
Errors and Misconceptions about Alcohol Use are Common Among Patients with Alcoholic Liver Disease
Jessica L. Mellinger, Robert J. Fontana, Michael Volk, Frederic Blow, Anna S. Lok

#1361
Direct Acting Antiviral Therapy is Associated with Shorter Time to HCC Recurrence but not Increased Risk of Recurrence

#1408
Treatment Patterns and Healthcare Costs by Lines of Therapy in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
Machaon Bonafede, Qian Cai, Prianka Singh, Neehar D. Parikh, Bruce E. Sill, Katherine Cappell, Krutika Jariwala-Parikh, Beata Korytowsky
Poster Sessions

Sunday, October 22, 2017 (con’t)  12:30 PM—2:00 PM

#1410
Serum Biomarkers Improve Prognostic Ability of BCLC Staging System
Saroja Bangaru, Wei Wei, Myron E. Schwartz, Neehar D. Parikh, Mindie H. Nguyen, Lewis R. Roberts, K. Rajender Reddy, Alex Befeler, Denise M. Harnois, Sudhir Srivastava, Jo Ann Rinaudo, Ziding Feng, Jorge A. Marrero

#1451
Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the United States
Neehar D. Parikh, Sherry Fu, Huiying Rao, Ming Yang, Yumeng Li, Corey Powell, Elizabeth Wu, Andy Lin, Baocai Xing, Wei Lai, Anna S. Lok

Monday, October 23, 2017  8:00 AM—5:30 PM

#1746
Hedgehog signaling regulates cell differentiation and proliferation in the biliary progenitor cell niche of the extrahepatic bile ducts in vivo, and in the biliary progenitor cell-derived organoids ex vivo
Nataliya Razumilava, Kais Zakharia, Christine Cieslak, Ramon Ocadiz Ruiz, Michael M. Hayes, Amanda L. Photenhauer, Nureen Mohamad Zaki, Theodore Welling, Scott Owens, Gregory J. Gores, Juanita L. Merchant

#1874
Cost-effectiveness of Screening for Hepatitis B Infection Prior to Solid Tumor Chemotherapy
Sirisha Grandhe, Gauree G. Konijeti, Monica A. Konerman, Jill A. Lane, Mark G. Shrim, Siddharth Singh, Rohit Loomba

#1896
High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada
Daryl Lau, Yona K. Cloonan, Lilia Ganova-Raeva, Stephen Liu, Raymond T. Chung, Mauricio Lisker-Melman, Kyon-Mi Chang, Obaid S. Shaikh, Harry L. Janssen, Anna S. Lok

#1904
ALT Flares are Associated with Increased Rates of HBeAg Seroconversion and HBV DNA Decline in Chronic Hepatitis B Infection: A Prospective Cohort Study from the Hepatitis B Research Network (HBRN)
Mayur Brahmania, Manuel Lombardero, Bettina E. Hansen, Norah Terrault, Anna S. Lok, Robert Perillo, Steven H. Belle, Adrian Biscaglie, Jordan J. Feld, William M. Lee, Michael W. Fried, Harry L. Janssen

#1907
Rate and Predictors of Phase Transition Among North American Adults with HbeAg-Negative Chronic Hepatitis B and Low Level Viremia: a Hepatitis B Research Network (HBRN) Study
#1931
Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients Receiving Anti-cancer Therapy
Jessica P. Hwang, Anna S. Lok, Carla L. Warneke, Sairah Ahmed, Harry A. Torres, Andrea G. Barbo, Maria Suarez-Almazor, Alessandra Ferrajoli

#2173
Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH
A. Sidney Barritt, Norman Gitlin, Samuel Klein, Anna S. Lok, Rohit Loomba, Laura Malahias, George E. DeMuth, Julie M. Crawford, K. Rajender Reddy, Huy N. Trinh, Miriam B. Vos, L. Michael Weiss, Kenneth Cusi, Brent A. Neuschwander-Tetri, Arum J. Sanyal

#2175
Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease
Monica A. Konerman, Patrick Walden, Elizabeth Jackson, Anna S. Lok, Melvyn Rubenfire

#2188
Body composition and muscle fitness associate with nonalcoholic fatty liver disease (NAFLD)
Vincent L. Chen, Andrew Wright, Yanhua Chen, Brian Halligan, Elizabeth K. Speliotes

#2198
NAFLD Patients with Metabolic Syndrome Have Significantly More Fat Deposition and Myosteatosis
Wei Zhang, Elizabeth Wu, Yi Wang Rui Huang, Sravanthi Kaza Anqi Li, Chao Sun, Huiying Rao, Lai Wei, Anna S. Lok, Grace L. Su

#2200
Diet/exercise programs are used by only one in five severely obese patients with biopsy-defined Nonalcoholic Fatty Liver Disease (NAFLD) advanced fibrosis in the Veterans Health Administration (VHA)
Yuval A. Patel, Elizabeth Gifford, Lisa M. Glass, Rebecca McNeil, Marsha J. Turner, Byungjoo Han, Dawn T. Provenzale, Steve S. Choi, Cynthia A. Moylan, Christine M. Hunt
# Michigan Medicine Liver Faculty

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Research Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frederick K. Askari, MD, PhD</td>
<td>Associate Professor of Internal Medicine</td>
<td>Wilson Disease, Medical Genetics, Liver Transplantation</td>
</tr>
<tr>
<td>Hari S. Conjeevaram, MD, MS</td>
<td>Professor of Internal Medicine, Medical Director of Liver Transplantation</td>
<td>Viral Hepatitis, Nonalcoholic Fatty Liver Disease, Acute and Chronic Liver Diseases, Liver Transplantation</td>
</tr>
<tr>
<td>Graham F. Brady, MD</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td>Nonalcoholic Fatty Liver Disease, Metabolic Liver Disease Bench Research, Cirrhosis</td>
</tr>
<tr>
<td>Robert J. Fontana, MD</td>
<td>Professor of Internal Medicine</td>
<td>Drug-induced Liver Disease, Viral Hepatitis, Acute Liver Failure, Cirrhosis, Liver Transplantation</td>
</tr>
<tr>
<td>Lisa Glass, MD</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td>General Hepatology, Nonalcoholic Fatty Liver Disease</td>
</tr>
<tr>
<td>Monica Konerman, MD, MS</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td>Nonalcoholic Fatty Liver Disease, Liver Transplantation, Clinical Risk Assessment for Progression of Chronic Liver Disease, Health Outcomes Research</td>
</tr>
<tr>
<td>Hellan Kwon, MD</td>
<td>Assistant Professor of Internal Medicine</td>
<td>General Hepatology, Nonalcoholic Fatty Liver Disease, Cirrhosis, Liver Transplantation</td>
</tr>
<tr>
<td>Anna S. F. Lok, MD, FRCP</td>
<td>Alice Lohrman Andrews Research Professor of Hepatology, Assistant Dean for Clinical Research, Professor of Internal Medicine</td>
<td>Viral Hepatitis, Cirrhosis, Health Outcomes Research, Hepatocellular Carcinoma</td>
</tr>
</tbody>
</table>
# Michigan Medicine Liver Faculty

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Email</th>
<th>Research Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Mellinger, MD, MS</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td><a href="mailto:jmelling@med.umich.edu">jmelling@med.umich.edu</a></td>
<td>Health Services Research, Alcoholic Liver Disease, Liver Transplantation</td>
</tr>
<tr>
<td>Neehar Parikh, MD, MS</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td><a href="mailto:ndparikh@med.umich.edu">ndparikh@med.umich.edu</a></td>
<td>Health Outcomes Research, Hepatocellular carcinoma, Liver Transplantation</td>
</tr>
<tr>
<td>Nataliya Razumilava, MD</td>
<td>Clinical Lecturer in Internal Medicine</td>
<td><a href="mailto:razumila@med.umich.edu">razumila@med.umich.edu</a></td>
<td>Cholangiocarcinoma Bench Research, Liver Cancer, Advanced Liver Diseases</td>
</tr>
<tr>
<td>Pratima Sharma, MD, MS</td>
<td>Associate Professor of Internal Medicine</td>
<td><a href="mailto:pratimas@med.umich.edu">pratimas@med.umich.edu</a></td>
<td>Liver Transplantation, Hepatocellular Carcinoma, Complications of Portal Hypertension</td>
</tr>
<tr>
<td>Elizabeth Speliotes, MD, PhD, MPH</td>
<td>Associate Professor of Internal Medicine, Associate Professor of Computational Medicine and Bioinformatics</td>
<td><a href="mailto:espeliot@med.umich.edu">espeliot@med.umich.edu</a></td>
<td>Nonalcoholic Fatty Liver Disease Bench Research, Obesity and Gastrointestinal Disease, Medical Genetics</td>
</tr>
<tr>
<td>Grace Su, MD</td>
<td>Professor of Internal Medicine</td>
<td><a href="mailto:gsu@med.umich.edu">gsu@med.umich.edu</a></td>
<td>Liver Disease, Autoimmune Hepatitis, CT Morphometry, Telemedicine</td>
</tr>
<tr>
<td>Andrew W. Tai, MD, PhD</td>
<td>Assistant Professor of Internal Medicine</td>
<td><a href="mailto:andrewwt@med.umich.edu">andrewwt@med.umich.edu</a></td>
<td>Viral Hepatitis Bench Research, Cirrhosis, Nonalcoholic Fatty Liver Disease</td>
</tr>
<tr>
<td>Elliot Tapper, MD</td>
<td>Assistant Professor of Internal Medicine</td>
<td><a href="mailto:etapper@med.umich.edu">etapper@med.umich.edu</a></td>
<td>General Hepatology, Hepatic Encephalopathy, Health Outcome Research, Quality Improvement</td>
</tr>
</tbody>
</table>
Hepatology, Liver Disease, and Transplant Clinics
(844) 233-0433 - Appointments
(734) 615-1825 - Liver Transplant Referrals

Taubman Health Center
1500 E. Medical Center Dr.
Ann Arbor, MI 48109
http://www.uofmhealth.org/our-locations/taubman-gastroenterology
(All Faculty)

Brighton Health Center
8001 Challis Rd.
Brighton, MI 48116
http://www.uofmhealth.org/our-locations/bhc-gastro
(Drs. Kwon, Konerman)

Canton Health Center
1501 N. Canton Rd.
Canton, MI 48187
http://www.uofmhealth.org/our-locations/cht-gastro
(Dr. Glass)

Northville Health Center
39901 Traditions Dr.
Northville, MI 48168
http://www.uofmhealth.org/our-locations/northville-health-center
(Drs. Lok, Sharma)
Other Hepatology Clinics

Mercy Health - Wege Building
Advanced Hepatology Clinic
310 Lafayette SE
Grand Rapids, MI 49503
(616) 685-5201
(Drs. Fontana, Conjeevaram)

Michigan Medicine - Metro Health
General Hepatology
2093 Health Dr. SW, Ste 302
Wyoming, MI 49519
(616) 252-5775
(Dr. Glass)

MidMichigan Health
Advanced Hepatology Clinic
4401 Campus Ridge Dr.
Midland, MI 48640
(989) 837-9200
(Drs. Parikh, Sharma)
Upcoming CME Programs

6th Annual Western Michigan Liver Round-Up
Saturday, November 4, 2017
Amway Grand Plaza Hotel
Grand Rapids, MI 49503

20th Annual Liver Disease Wrap-Up
Saturday, December 2, 2017
The Inn at St. John’s
Plymouth, MI 48170

Liver Update
Saturday, March 24, 2018
Midland, MI 48640

13th Annual Advanced Liver Disease and Transplantation Update 2018
Friday, May 11, 2018
Sheraton Detroit Novi Hotel
Novi, MI 48375

Michigan Medicine on Twitter!
@MichiganLiver on Twitter
Follow us, stay connected, GO BLUE!